📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma - Authors' reply. (2017)

First Author: Smyth EC

Attributed to: CANCER: Trials with potential global reach and other challenging trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(17)30261-9

PubMed Identifier: 28495289

Publication URI: http://europepmc.org/abstract/MED/28495289

Type: Journal Article/Review

Volume: 18

Parent Publication: The Lancet. Oncology

Issue: 5

ISSN: 1470-2045